carmustine has been researched along with Immunoblastic Lymphadenopathy in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Immunoblastic Lymphadenopathy: A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of acute myocardial ischemia following carmustine treatment during the BEAM regimen." | 3.71 | Acute myocardial ischemia after high-dose therapy with BEAM regimen. ( Gallet, B; Genet, P; Jondeau, K; Laribi, K; Lionnet, F; Pulik, M; Touahri, T, 2002) |
| "Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity." | 1.35 | High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. ( Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genet, P | 1 |
| Pulik, M | 1 |
| Gallet, B | 1 |
| Lionnet, F | 1 |
| Jondeau, K | 1 |
| Touahri, T | 1 |
| Laribi, K | 1 |
| Kyriakou, C | 1 |
| Canals, C | 1 |
| Goldstone, A | 1 |
| Caballero, D | 1 |
| Metzner, B | 1 |
| Kobbe, G | 1 |
| Kolb, HJ | 1 |
| Kienast, J | 1 |
| Reimer, P | 1 |
| Finke, J | 1 |
| Oberg, G | 1 |
| Hunter, A | 1 |
| Theorin, N | 1 |
| Sureda, A | 1 |
| Schmitz, N | 1 |
2 other studies available for carmustine and Immunoblastic Lymphadenopathy
| Article | Year |
|---|---|
Acute myocardial ischemia after high-dose therapy with BEAM regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etopo | 2002 |
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarab | 2008 |